Andrew Do

8PUBLICATIONS
70CO-AUTHORS
Molecular targetsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.

Sarah Waliany, Alissa J Cooper, Stephen V Liu

|Nov 04, 2023
Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution.

Jaime L Schneider, Khvaramze Shaverdashvili, Mari Mino-Kenudson

|Jul 12, 2023
Integrated Radiology, Pathology, and Pharmacy Program to Accelerate Access to Osimertinib.

Ibiayi Dagogo-Jack, Amanda Manoogian, Nicholas Jessop

|Mar 09, 2021
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.

Jessica J Lin, Noura J Choudhury, Satoshi Yoda

|Aug 18, 2020
Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition.

Jessica J Lin, Adam Langenbucher, Pranav Gupta

Pageof 2